MD Anderson Cancer Center Institute Senior Research Scientist - Translational Biomarker Discovery in Houston, Texas
The Institute Senior Research Scientist - Translational Biomarker Discovery will lead our translational biology discovery group that is focused on discovering and developing biomarkers in the preclinical and clinical settings to inform on tumor biology in the context of drug development. The position requires working within a cross-functional team while utilizing state-of-the-art preclinical models to discover, validate and translate exploratory biomarkers into informative translational assays that can be applied to clinical samples. These efforts will enable assessment of therapeutic agent activity in patient samples as part of ongoing clinical trials. By incorporating biological insights into translatable biomarkers, we seek to advance therapeutics under development by IACS, the MD Anderson Moon Shots disease teams, and our corporate partners.
We are seeking a highly motivated in vivo biologist with experience in an industry or industry-like environment using a broad array of methods to investigate how new drug candidates and therapeutic combinations impact tumor biology. This position will require effective management of associate scientists, strong scientific leadership and effective engagement and integration with multi-disciplinary drug discovery teams.
The mission of The Center for Co-Clinical Trials (CCCT) is to integrate biological insights with drug discovery expertise to accelerate the development of innovative targeted cancer therapeutics. The CCCT is a ground-breaking translational research team that partners with world-class drug discovery scientists at the Institute for Applied Cancer Science (IACS) along with their industry-modelled in vivo pharmacology unit and state-of-the-art computational biology infrastructure. CCCT's cross-functional teams aim to deliver biological insights regarding genetic and functional contributions that influence tumor response to novel therapeutic agents or regimens. As part of the MD Anderson Cancer Center Moon Shots initiative, the capabilities of the CCCT, in concert with IACS, support the institution's academic and clinical research programs to help us reach our goal of delivering safer, more effective treatments to our patients.
Salary Range: Min $112,000 - Mid $140,000 - Max $168,000
· Drive efforts to assess impact of novel therapeutics and combinations on the hallmarks of cancer in preclinical and clinical samples.
· Collaborate with computational biologists, program biologists and in vivo pharmacologists to identify, validate and develop pharmacodynamic and patient selection biomarkers that are suitable for preclinical assessment and translation into the clinic.
· Utilize in situ and flow methods for tumor immune profiling in response to therapeutic intervention.
· Work with in vivo pharmacologists, disease expert pathologists and non-invasive imaging experts to enable the molecular and pathological characterization of state-of-the-art preclinical models of cancer.
· Lead immunohistochemistry/immunofluorescence efforts through internal effort and outsourcing to generate qualitative and quantitative assessment of tumor biology.
· Identify, evaluate and implement novel technologies to support translational biomarker activities.
· Provide mentorship, professional development, guidance and leadership to a team of dedicated research and associate scientists.
· Review and report data for regulatory submissions.
· Employ and ensure safe lab practices and maintain research records and laboratory notes.
Required: Master's degree in one of the natural sciences.
Preferred: Ph.D. in Pharmacology, cancer biology, immune-oncology or related discipline
Required: Eleven years of relevant research laboratory experience. With preferred degree, five years of required experience.
Preferred: A minimum of 4 years industry-like experience (at least 7 years preferred).
•Strong working knowledge of oncology disease processes and preclinical models.
•Experience using flow cytometry/immunohistochemistry to measure immune cell activity in tumors.
•Experience working with mouse models of cancer to assess therapeutic impact on tumor biology.
•Experience using various methods to characterize and evaluate in vivo target and pathway biology as part of drug discovery efforts. This includes molecular profiling, histopathology, immunohistochemistry/immunofluorescence, non-invasive imaging and the use of blood-based methods.
•Experience establishing pharmacokinetic/pharmacodynamic relationships in preclinical models of cancer.
•Demonstrated ability for creative thinking and problem solving.
•Demonstrated ability to collaborate effectively in a multi-disciplinary team.
•Excellent leadership, communication and organizational skills.
•Experience in managing of a team of scientists.
It is the policy of The University of Texas MD Anderson Cancer Center to provide equal employment opportunity without regard to race, color, religion, age, national origin, sex, gender, sexual orientation, gender identity/expression, disability, protected veteran status, genetic information, or any other basis protected by institutional policy or by federal, state or local laws unless such distinction is required by law. http://www.mdanderson.org/about-us/legal-and-policy/legal-statements/eeo-affirmative-action.html